Five-Year Medium-Term Management Plan “Reach Beyond, Together”
First written in FY2023. 3 of 6 entries say "Advanced", first in FY2024. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「Through the establishment of an overseas development structure and active development activities, the global Phase 3 clinical trial of JR-141 reached a stage at which patient enrolment could be completed ahead of schedule.」
Under the 5-year Medium-Term Management Plan, the Company advanced the global Phase 3 trial of JR-141 through the establishment of an overseas development structure, reaching the stage at which enrolment could be completed ahead of schedule. - FY2025AdvancedAnnual report
「The Group launched the 5-year Medium-Term Management Plan, "Reach Beyond, Together," in fiscal 2023. Under the plan, it has continued unprecedented challenges to deliver lysosomal disease treatments using its proprietary blood-brain barrier penetration technology, J-Brain Cargo®, to patients as soon as possible. Through the establishment of an overseas development structure and active development activities, the global Phase 3 clinical trial of JR-141 reached a stage at which patient enrolment could be completed ahead of schedule.」
Under the 5-year Medium-Term Management Plan, the Company established an overseas development structure, and the global Phase 3 trial of JR-141 progressed to a stage at which patient enrolment could be completed ahead of schedule. - FY2024AdvancedAnnual report
「In May 2023, the Company announced its 5-year Medium-Term Management Plan, "Reach Beyond, Together." The plan aims to further strengthen the strengths identified in the previous medium-term management plans, "Hiyaku" and "Henkaku," bring together the unique research and development capabilities and manufacturing capabilities cultivated since the Company's founding, and maximize business value through "what only JCR can do."」
The new 5-year plan specified 5 initiatives, including applications of J-Brain Cargo®, global manufacturing and quality assurance, early commercialization of rare-disease development products and human-resource development. The plan targets the initiation of clinical trials for 5 lysosomal disease treatments during fiscal 2023–2027. - FY2024-Q3RestatedAnnual report
「There have been no material changes to the management policies, management strategies or other matters established by our group during the cumulative third quarter of the fiscal year.」
The Company reconfirmed that there had been no material changes to its management policies, management strategies or related matters, including the 5-year Medium-Term Management Plan, "Reach Beyond, Together." - FY2024-Q2RestatedAnnual report
「There have been no material changes to the management policy or strategy established by our Group during the second quarter of the current consolidated cumulative period.」
The Company reconfirmed that there had been no material changes to its management policies, management strategies or related matters, including the 5-year Medium-Term Management Plan, "Reach Beyond, Together." - FY2023First statedAnnual report
「In May 2023, the Company announced its 5-year Medium-Term Management Plan, "Reach Beyond, Together." The plan is positioned as the process of advancing toward the realization of the Company's desired vision: to further strengthen the strengths identified in the previous medium-term management plans, "Hiyaku" and "Henkaku," bring together the unique research and development capabilities and manufacturing capabilities cultivated since the Company's founding, and pursue "what only JCR can do" for patients and their families, even in diseases affecting extremely few patients.」
Building on the previous plans, "Hiyaku" and "Henkaku," the Company announced a new 5-year plan in May 2023. The plan aims to bring together its research and development capabilities and manufacturing capabilities and pursue responses to rare diseases that only the Company can provide.